NCT06843005 Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease
| NCT ID | NCT06843005 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhang longjiang,MD |
| Condition | Major Adverse Cardiovascular Events (MACE) |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,100 participants |
| Start Date | 2025-02-28 |
| Primary Completion | 2028-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 3,100 participants in total. It began in 2025-02-28 with a primary completion date of 2028-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective of this study is to evaluate whether a management strategy based on coronary computed tomography angiography (CCTA) for patients with non-obstructive coronary artery disease can improve the LDL-C target achievement rate compared to a traditional management strategy without follow-up CCTA, thereby reducing the incidence of major adverse cardiovascular and cerebrovascular events over a 3 years period, including all-cause mortality, myocardial infarction, ischemia driven revascularation and stroke.
Eligibility Criteria
Inclusion Criteria: 1. Age between 18 and 80 years old; 2. Known patients with non-obstructive coronary artery disease (disease duration ≥2 years); 3. Patients who agree to undergo follow-up CCTA examinations and cooperate in completing follow-up observations. Exclusion Criteria: 1. Patients who have experienced ACS or PCI/CABG; 2. Patients who have experienced adverse cardiovascular and cerebrovascular events; 3. Patients who have undergone follow-up CCTA or DSA examinations before enrollment; 4. Patients with severe hepatic and renal dysfunction; 5. Patients with contraindications to CCTA examinations; 6. Patients with poor initial CCTA image quality or data loss.
Contact & Investigator
Trail Manager
STUDY CHAIR
Jinling Hospital,Nanjing University School of Medicine,Nanjing,China
Frequently Asked Questions
Who can join the NCT06843005 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Major Adverse Cardiovascular Events (MACE). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06843005 currently recruiting?
Yes, NCT06843005 is actively recruiting participants. Contact the research team at kevinzhlj@163.com for enrollment information.
Where is the NCT06843005 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT06843005 clinical trial?
NCT06843005 is sponsored by Zhang longjiang,MD. The principal investigator is Trail Manager at Jinling Hospital,Nanjing University School of Medicine,Nanjing,China. The trial plans to enroll 3,100 participants.